Concepedia

Publication | Open Access

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer

DOIFull Paper Access

34

Citations

35

References

2013

Year

Nicolai A. Schultz, Ib Jarle Christensen, Jens Werner, Nathalia A. Giese, Benny Vittrup Jensen, Ole Larsen, Jon Kroll Bjerregaard, Per Pfeiffer, Dan Calatayud, Svend Erik Nielsen,
PLoS ONE

Abstract

Plasma YKL-40 and IL-6 had less diagnostic impact than CA 19.9. Combination of pretreatment YKL-40, IL-6, and CA 19.9 may have clinical value to identify pancreatic cancer patients with the poorest prognosis.

References

YearCitations

Page 1